Q1 2025 EPS Estimates for Cencora, Inc. Boosted by Leerink Partnrs (NYSE:COR)

Cencora, Inc. (NYSE:COR) – Investment analysts at Leerink Partnrs increased their Q1 2025 earnings per share estimates for Cencora in a report released on Wednesday, July 31st. Leerink Partnrs analyst M. Cherny now expects that the company will earn $3.46 per share for the quarter, up from their previous estimate of $3.45. The consensus estimate for Cencora’s current full-year earnings is $13.56 per share. Leerink Partnrs also issued estimates for Cencora’s Q4 2025 earnings at $3.66 EPS, FY2025 earnings at $14.96 EPS and FY2026 earnings at $16.60 EPS.

Cencora (NYSE:COR) last released its earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, beating analysts’ consensus estimates of $3.18 by $0.16. The business had revenue of $74.20 billion during the quarter, compared to the consensus estimate of $73.32 billion. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The company’s revenue for the quarter was up 10.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.92 EPS.

Other equities research analysts have also issued research reports about the company. Robert W. Baird upped their target price on Cencora from $285.00 to $287.00 and gave the company an “outperform” rating in a research report on Thursday, August 1st. StockNews.com raised shares of Cencora from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 2nd. SVB Leerink reiterated an “outperform” rating and set a $275.00 target price on shares of Cencora in a research report on Thursday, June 27th. Citigroup raised their price target on shares of Cencora from $265.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, April 30th. Finally, Wells Fargo & Company upped their price objective on shares of Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a report on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $249.63.

Cencora Price Performance

COR stock opened at $239.82 on Monday. The company has a quick ratio of 0.53, a current ratio of 0.89 and a debt-to-equity ratio of 3.93. The company’s fifty day simple moving average is $229.77 and its 200 day simple moving average is $231.65. Cencora has a 12-month low of $171.65 and a 12-month high of $247.66. The firm has a market cap of $47.83 billion, a price-to-earnings ratio of 26.24, a PEG ratio of 1.68 and a beta of 0.45.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 26th. Shareholders of record on Friday, August 9th will be given a $0.51 dividend. This represents a $2.04 dividend on an annualized basis and a yield of 0.85%. The ex-dividend date of this dividend is Friday, August 9th. Cencora’s payout ratio is 22.32%.

Insider Buying and Selling at Cencora

In other news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the completion of the transaction, the insider now directly owns 19,980,000 shares of the company’s stock, valued at $4,806,388,800. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the transaction, the insider now directly owns 19,980,000 shares of the company’s stock, valued at approximately $4,806,388,800. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Gina Clark sold 27,093 shares of the firm’s stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $216.07, for a total transaction of $5,853,984.51. Following the sale, the executive vice president now owns 15,158 shares of the company’s stock, valued at approximately $3,275,189.06. The disclosure for this sale can be found here. In the last 90 days, insiders sold 6,337,283 shares of company stock worth $1,476,300,791. Insiders own 15.80% of the company’s stock.

Hedge Funds Weigh In On Cencora

Institutional investors have recently bought and sold shares of the company. Rise Advisors LLC bought a new position in Cencora in the 1st quarter worth approximately $25,000. New Millennium Group LLC bought a new position in shares of Cencora in the second quarter worth $26,000. Legacy Bridge LLC purchased a new position in shares of Cencora in the first quarter valued at $27,000. TCTC Holdings LLC bought a new stake in shares of Cencora during the 1st quarter valued at $29,000. Finally, TFO Wealth Partners LLC purchased a new stake in Cencora during the 1st quarter worth about $30,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.